Alexander G. Goglia

Alexander G. Goglia

Auto-generated profile, based on publicly available information

Alexander G. Goglia

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
WPWilliam R. Polkinghorn
William R. Polkinghorn
JPJoel S. Parker
Joel S. Parker
MLMan X. Lee
Man X. Lee
EKElizabeth M. Kass
Elizabeth M. Kass
DSDaniel Spratt
Daniel Spratt
CSCharles L. Sawyers
Charles L. Sawyers
We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy synergizes with ionizing radiation. Using a model of castration-resistant prostate cancer, we show that second-generation antiandrogen therapy results in downregulation of DNA repair genes. Next, we demonstrate that primary prostate cancers display a significant spectrum of AR transcriptional output, which correlates with expression of a set of DNA repair genes. Using RNA-seq and ChIP-seq, we define which of these DNA repair genes are both induced by androgen and represent direct AR targets. We establish that prostate cancer cells treated with ionizing radiation plus androgen demonstrate enhanced DNA repair and decreased DNA damage and furthermore that antiandrogen treatment causes increased DNA damage and decreased clonogenic survival. Finally, we demonstrate that antiandrogen treatment results in decreased classical nonhomologous end-joining. Significance: We demonstrate that the AR regulates a network of DNA repair genes, providing a potential mechanism by which androgen deprivation synergizes with radiotherapy for prostate cancer. Cancer Discov; 3(11); 1245–53. ©2013 AACR. See related commentary by Bartek et al., p. 1222 This article is highlighted in the In This Issue feature, p. 1207

1 July 2018 in Cell Systems
Verified
Journal Article
Closed access
LTLukas Bahati Tanner
Lukas Bahati Tanner
AGAlexander G. Goglia
Alexander G. Goglia
MWMonica H. Wei
Monica H. Wei
TSTalen Sehgal
Talen Sehgal
LPLance R. Parsons
Lance R. Parsons
JRJoshua D. Rabinowitz
Joshua D. Rabinowitz

13 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAgnieszka A. Gil
Agnieszka A. Gil
César Carrasco-LópezCésar Carrasco-López
César Carrasco-López
LZLiyuan Zhu
Liyuan Zhu
EZEvan M. Zhao
Evan M. Zhao
PRPavithran T. Ravindran
Pavithran T. Ravindran
JTJared E. Toettcher
Jared E. Toettcher
A growing number of optogenetic tools have been developed to reversibly control binding between two engineered protein domains. In contrast, relatively few tools confer light-switchable binding to a generic target protein of interest. Such a capability would offer substantial advantages, enabling photoswitchable binding to endogenous target proteins in cells or light-based protein purification in vitro. Here, we report the development of opto-nanobodies (OptoNBs), a versatile class of chimeric photoswitchable proteins whose binding to proteins of interest can be enhanced or inhibited upon blue light illumination. We find that OptoNBs are suitable for a range of applications including reversibly binding to endogenous intracellular targets, modulating signaling pathway activity, and controlling binding to purified protein targets in vitro. This work represents a step towards programmable photoswitchable regulation of a wide variety of target proteins.

1 February 2019 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
AGAlexander G Goglia
Alexander G Goglia
JTJared E Toettcher
Jared E Toettcher

18 March 2020 in Cell Systems
Verified
Journal Article
Closed access
AGAlexander G. Goglia
Alexander G. Goglia
MWMaxwell Z. Wilson
Maxwell Z. Wilson
SJSiddhartha G. Jena
Siddhartha G. Jena
JSJillian Silbert
Jillian Silbert
LBLena P. Basta
Lena P. Basta
JTJared E. Toettcher
Jared E. Toettcher

12 April 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RBRanjit S. Bindra
Ranjit S. Bindra
AGAlexander G. Goglia
Alexander G. Goglia
MJMaria Jasin
Maria Jasin
SPSimon N. Powell
Simon N. Powell
Double-strand break (DSB) repair pathways are critical for the maintenance of genomic integrity and the prevention of tumorigenesis in mammalian cells. Here, we present the development and validation of a novel assay to measure mutagenic non-homologous end-joining (NHEJ) repair in living cells, which is inversely related to canonical NHEJ and is based on the sequence-altering repair of a single site-specific DSB at an intrachromosomal locus. We have combined this mutagenic NHEJ assay with an established homologous recombination (HR) assay such that both pathways can be monitored simultaneously. In addition, we report the development of a ligand-responsive I-SceI protein, in which the timing and kinetics of DSB induction can be precisely controlled by regulating protein stability and cellular localization in cells. Using this system, we report that mutagenic NHEJ repair is suppressed in growth-arrested and serum-deprived cells, suggesting that end-joining activity in proliferating cells is more likely to be mutagenic. Collectively, the novel DSB repair assay and inducible I-SceI will be useful tools to further elucidate the complexities of NHEJ and HR repair.